• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Novartis: Divestments, Mergers, and Acquisitions Create a Diverse Healthcare Company Product Image

Novartis: Divestments, Mergers, and Acquisitions Create a Diverse Healthcare Company

  • Published: December 2012
  • Region: Global
  • 19 Pages
  • MarketLine

Introduction

In 1996 Ciba-Geigy merged with Sandoz to form Novartis. In 1997, 2000, 2006, and 2007 it divested its specialty chemicals, agribusiness, nutrition, and medical nutrition and baby foods businesses, respectively. Novartis has also made acquisitions to strengthen its position in the healthcare market, and now generates 100% of revenues from healthcare, and operates through five diverse segments.

Features and benefits

- MarketLine Case Studies describe topics such as innovative products, business models, and significant company acquisitions.

- Fact-based and presented in an accessible style, they explain the rationale of commercial decisions and illustrate wider market and economic trends.

Highlights

The global population is growing older, and Novartis Pharmaceuticals provides products aimed at high- and middle-income countries, where a higher proportion of the population reaches old age. Novartis Pharmaceuticals' product lines reflect the most common causes of death in these countries.
While vaccines are estimated to save the lives of over 3 million people annually, the World Health Organization (WHO) estimates that over 3 million READ MORE >

OVERVIEW

- Catalyst

- Summary

NOVARTIS’S ORIGINS TRACE BACK TO THREE COMPANIES

- Company origins
-- Geigy was a dye producer
-- Ciba was a chemicals company
-- Sandoz was a pharmaceuticals, nutrition and agribusiness/chemicals company
-- Novartis was founded through a merger

- Mergers, acquisitions, and divestments have made Novartis a leading healthcare company
-- Novartis spun off its chemical, agribusiness, and nutrition units
-- Novartis expanded its pharmaceuticals business with acquisitions

- Novartis’s different segments address the different needs of a changing population
-- The common causes of death have changed significantly in the last 100 years
-- Novartis Pharmaceuticals largely addresses the healthcare needs of middle- and high-income countries
-- Novartis Vaccines and Diagnostics largely addresses the needs of low-income countries
-- The company is expanding geographically
-- Animal Health and OTC provide stable growth

CONCLUSION

- Novartis’s diversity and investment in R&D will “improve the long-term growth prospects of the business”

APPENDIX

- Definitions

- Sources

- Further Reading

- Ask the analyst

- About MarketLine

- Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos